Major positive events in 2024 include India’s first solar-powered remote village, the discovery of plastic-decomposing worms, ...

Sangamo (SGMO) stock faces challenges as Pfizer terminates partnership for hemophilia A gene therapy, impacting share price ...

An update from JCR Pharmaceuticals Co., Ltd. ( (JP:4552) ) is now available.

JCR Pharmaceuticals Co., Ltd. ( (JP:4552) ) has issued an update.

Amicus Therapeutics’ first oral drug for the rare condition Fabry disease has been approved by the FDA, giving patients an alternative to conventional injected enzyme replacement therapy.

ACT-10041239 is under clinical development by Idorsia Pharmaceutical and currently in Phase I for Multiple Sclerosis.

Sangamo Therapeutics (NASDAQ:SGMO – Get Free Report)‘s stock had its “buy” rating reaffirmed by equities researchers at HC ...

Sangamo Therapeutics (NASDAQ:SGMO – Free Report) had its price objective reduced by Jefferies Financial Group from $7.00 to ...

Chiesi GRD has an initial focus in developing therapies for lysosomal storage disorders (LSDs), including Fabry disease, as well as other rare diseases in haematology and opthalmology indications.

A breaking-news bulletin linked to this story inaccurately characterized the number of years that have passed since Sangamo Therapeutics shares lost as much in a single session. It has been since 2008 ...

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be ...

JCR Pharmaceuticals Co., Ltd. (TOKYO:4552; "JCR") and Modalis Therapeutics Corporation (TOKYO:4883; "Modalis") today announced that they have validated the initial proof of concept in a joint research ...